VEGFA and pancreatic neuroendocrine tumor: Casanovas and colleagues found that VEGFR-2 inhibition of RIP1-Tag2 mouse pancreatic endocrine tumors led to an increase in intratumoral hypoxia along with increased tumor invasiveness and liver metastases [32, 40], and Ebos et al. found that sunitinib (which targets VEGF and other pathways) increased liver and lung metastases for both experimental and spontaneous metastases [33].